secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001193125-26-148853
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix reports prelim Q1 net sales $196.7M, realigns spine leadership, Reinhardt to depart
--------------------------------------------------------------------------------

- Preliminary Q1 net sales $196.7M; reported constant currency +0.4%, pro forma constant currency +2.7% YoY.
- FY 2026 guidance reaffirmed: net sales $850M-$860M, adj. EBITDA $95M-$98M, positive FCF ex-legal settlements.
- President, Global Spine Max Reinhardt to depart on/about June 12, 2026; role eliminated in realignment.
- Key spine leaders (Bannigan, Sienkiewicz, Winge) now report directly to CEO; Fisher expands to Biologics.
- M6 disc discontinuation impact fell to $0.3M in Q1 from $4.4M in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000119312526148853/0001193125-26-148853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000119312526148853/ofix-20260409.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-148853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer